Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase Ia/Ib, first-in-human, open label, multicenter, dose-escalation and dose-expansion study of a novel NanoZolid-docetaxel depot formulation (NZ-DTX Depot) given as an intratumoral injection in patients with advanced solid tumors

Trial Profile

A phase Ia/Ib, first-in-human, open label, multicenter, dose-escalation and dose-expansion study of a novel NanoZolid-docetaxel depot formulation (NZ-DTX Depot) given as an intratumoral injection in patients with advanced solid tumors

Planning
Phase of Trial: Phase I

Latest Information Update: 06 Feb 2019

At a glance

  • Drugs Docetaxel (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms NZ-DTX-001
  • Sponsors LIDDS
  • Most Recent Events

    • 06 Feb 2019 According to a LIDDS media release, Dr. Charlotta Gauffin, Head of Clinical Development, will join the company in March 2019 and will be responsible for this study
    • 05 Feb 2019 According to a LIDDS media release, the company will now initiate a collaboration with a competent phase I clinical site in Denmark.
    • 05 Feb 2019 According to a LIDDS media release, the Danish Medicines Agency (DKMA) has now approved to conduct this study (NZ-DTX-001) in Denmark.This adds another Scandinavian clinic to this trial in addition to Karolinska University Hospital (Sweden).LIDDS expects to enroll the first patients in this study in Q1 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top